NCT05747664View on ClinicalTrials.gov

To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

DWP16001

0.3mg

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY